Drug-nutrient interactions

Journal of Parenteral and Enteral Nutrition

Volumn 37, Issue 4, 2013, Pages 450-459

  Chan, Lingtak Neander ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

drug nutrient interactions; enteral nutrition; intestinal transporters; nutrition support

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CALCIUM; CARNITINE; CARRIER PROTEIN; CEPHALOSPORIN DERIVATIVE; CIMETIDINE; CIPROFLOXACIN; CYCLOSPORIN; DAUNORUBICIN; ENALAPRIL; FEXOFENADINE; IMATINIB; IRINOTECAN; LEVOFLOXACIN; LEVOTHYROXINE; LITHIUM; MITOXANTRONE; OLIGOPEPTIDE TRANPORTER TYPE 1; ORGANIC ANION TRANSPORTER 1; ORGANIC CATION TRANSPORTER TYPE 2; OSELTAMIVIR; QUINIDINE; RASAGILINE; SALAZOSULFAPYRIDINE; SODIUM; SPIRONOLACTONE; TYRAMINE; UNCLASSIFIED DRUG; VALACICLOVIR; VALPROIC ACID;

ABSORPTION; ARTICLE; CARNITINE DEFICIENCY; CHEMICAL INTERACTION; CLASSIFICATION; COMORBIDITY; CRITICALLY ILL PATIENT; DIET SUPPLEMENTATION; DRUG BLOOD LEVEL; DRUG INTERACTION; DRUG NUTRIENT INTERACTION; DRUG PROTEIN BINDING; ELIMINATION REACTION; ENTERIC FEEDING; FOOD DRUG INTERACTION; GRAPEFRUIT JUICE; HYPERTENSION; HYPOTHYROIDISM; PARENTERAL NUTRITION; PHYSIOLOGY; POLYPHARMACY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SAFETY; SODIUM RESTRICTION; TOXICITY; TREATMENT FAILURE; TREATMENT WITHDRAWAL;

DRUG-NUTRIENT INTERACTIONS; ENTERAL NUTRITION; INTESTINAL TRANSPORTERS; NUTRITION SUPPORT;

DISEASE MANAGEMENT; FOOD-DRUG INTERACTIONS; HUMANS;

EID: 84879211753     PISSN: 01486071     EISSN: None     Source Type: Journal    
DOI: 10.1177/0148607113488799     Document Type: Article

References (50)

1. Tepeš B. Long-term acid inhibition: benefits and harms. Dig Dis. 2011 ; 29 (5). 476-481
2. Sarzynski E, Puttarajappa C, Xie Y, Grover M, Laird-Fick H. Association between proton pump inhibitor use and anemia: a retrospective cohort study. Dig Dis Sci. 2011 ; 56 (8). 2349-2353
3. Long AN, Atwell CL, Yoo W, Solomon SS. Vitamin B(12) deficiency associated with concomitant metformin and proton pump inhibitor use. Diabetes Care. 2012 ; 35 (12). e84
4. Ito T, Jensen RT. Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium. Curr Gastroenterol Rep. 2010 ; 12 (6). 448-457
5. McColl KE. Effect of proton pump inhibitors on vitamins and iron. Am J Gastroenterol. 2009 ; 104: S5 - S9
6. Lee RH, Lyles KW, Colón-Emeric C. A review of the effect of anticonvulsant medications on bone mineral density and fracture risk. Am J Geriatr Pharmacother. 2010 ; 8 (1). 34-46
7. Farhat G, Yamout B, Mikati MA, Demirjian S, Sawaya R, El-Hajj Fuleihan G. Effect of antiepileptic drugs on bone density in ambulatory patients. Neurology. 2002 ; 58 (9). 1348-1353
8. Feldkamp J, Becker A, Witte OW, Scharff D, Scherbaum WA. Long-term anticonvulsant therapy leads to low bone mineral density - evidence for direct drug effects of phenytoin and carbamazepine on human osteoblast-like cells. Exp Clin Endocrinol Diabetes. 2000 ; 108 (1). 37-43
9. Sconce EA, Avery PJ, Wynne HA, Kamali F. Vitamin K epoxide reductase complex subunit 1 (VKORC1) polymorphism influences the anticoagulation response subsequent to vitamin K intake: a pilot study. J Thromb Haemost. 2008 ; 6 (7). 1226-1228
10. Pavani A, Naushad SM, Rupasree Y, et al. Optimization of warfarin dose by population-specific pharmacogenomic algorithm. Pharmacogenomics J. 2012 ; 12 (4). 306-311
11. Chan L-N Modern Nutrition in Health and Disease. 10 th ed.Philadelphia, PA: Lippincott Williams & Wilkins; 2006:1539-1553. Shils ME Shike M Olson JA, ed. Philadelphia, PA: Lippincott Williams & Wilkins ; 1539-1553.
12. Jin DY, Tie JK, Stafford DW. The conversion of vitamin K epoxide to vitamin K quinone and vitamin K quinone to vitamin K hydroquinone uses the same active site cysteines. Biochemistry. 2007 ; 46 (24). 7279-7283
13. Stafford DW. The vitamin K cycle. J Thromb Haemost. 2005 ; 3 (8). 1873-1878
14. U.S. Food and Drug Administration (FDA). Guidance for Industry: Food-effect Bioavailability and Fed Equivalence Studies. Rockville, MD: FDA; 2002. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm070241.pdf
15. Boudry G, David ES, Douard V, Monteiro IM, Le Huërou-Luron I, Ferraris RP. Role of intestinal transporters in neonatal nutrition: carbohydrates, proteins, lipids, minerals, and vitamins. J Pediatr Gastroenterol Nutr. 2010 ; 51 (4). 380-401
16. Grandvuinet AS, Vestergaard HT, Rapin N, Steffansen B. Intestinal transporters for endogenic and pharmaceutical organic anions: the challenges of deriving in-vitro kinetic parameters for the prediction of clinically relevant drug-drug interactions. J Pharm Pharmacol. 2012 ; 64 (11). 1523-1548
17. Hediger MA, Romero MF, Peng JB, Rolfs AB, Takanaga A, Bruford EA. The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteins. Pflugers Arch. 2004 ; 447: 465-468
18. Sai Y. Biochemical and molecular pharmacological aspects of transporters as determinants of drug disposition. Drug Metab Pharmacokinet. 2005 ; 20: 91-99
19. Shugarts S, Benet L-Z. The role of transporters in the pharmacokinetics of orally administered drugs. Pharm Res. 2009 ; 26: 2039-2054
20. Estudante M, Morais JG, Soveral G, Benet LZ. Intestinal drug transporters: an overview. Adv Drug Deliv Rev. :
21. Terada T, Shimada Y, Pan X, et al. Expression profiles of various transporters for oligopeptides, amino acids and organic ions along the human digestive tract. Biochem Pharmacol. 2005 ; 70: 1756-1763
22. Thwaites DT, Anderson CM. The SLC36 family of proton-coupled amino acid transporters and their potential role in drug transport. Br J Pharmacol. 2011 ; 164: 1802-1816
23. Anderson CM, Thwaites DT. Hijacking solute carriers for proton-coupled drug transport. Physiology (Bethesda). 2010 ; 25 (6). 364-377
24. Thwaites DT, Anderson CM. H+-coupled nutrient, micronutrient and drug transporters in the mammalian small intestine. Exp Physiol. 2007 ; 92 (4). 603-619
25. Roth M, Obaidat A, Hagenbuch B. OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. Br J Pharmacol. 2012 ; 165 (5). 1260-1287
26. Obaidat A, Roth M, Hagenbuch B. The expression and function of organic anion transporting polypeptides in normal tissues and in cancer. Annu Rev Pharmacol Toxicol. 2012 ; 52: 135-151
27. Verrotti A, Trotta D, Morgese G, Chiarelli F. Valproate-induced hyperammonemic encephalopathy. Metab Brain Dis. 2002 ; 17 (4). 367-373
28. Chopra A, Kolla BP, Mansukhani MP, Netzel P, Frye MA. Valproate-induced hyperammonemic encephalopathy: an update on risk factors, clinical correlates and management. Gen Hosp Psychiatry. 2012 ; 34 (3). 290-298
29. Coppola G, Epifanio G, Auricchio G, Federico RR, Resicato G, Pascotto A. Plasma free carnitine in epilepsy children, adolescents and young adults treated with old and new antiepileptic drugs with or without ketogenic diet. Brain Dev. 2006 ; 28 (6). 358-365
30. Moreno FA, Macey H, Schreiber B. Carnitine levels in valproic acid-treated psychiatric patients: a cross-sectional study. J Clin Psychiatry. 2005 ; 66 (5). 555-558
31. Okamura M, Terada T, Katsura T, Saito H, Inui K. Inhibitory effect of zinc on PEPT1-mediated transport of glycylsarcosine and beta-lactam antibiotics in human intestinal cell line Caco-2. Pharm Res. 2003 ; 20 (9). 1389-1393
32. Okamura M, Terada T, Katsura T, Inui K. Inhibitory effect of zinc on the absorption of beta-lactam antibiotic ceftibuten via the peptide transporters in rats. Drug Metab Pharmacokinet. 2008 ; 23 (6). 464-468
33. Morimoto K, Kishimura K, Nagami T, et al. Effect of milk on the pharmacokinetics of oseltamivir in healthy volunteers. J Pharm Sci. 2011 ; 100 (9). 3854-3861
34. Salazar JA, Poon I, Nair M. Clinical consequences of polypharmacy in elderly: expect the unexpected, think the unthinkable. Expert Opin Drug Saf. 2007 ; 6 (6). 695-704
35. Valuck RJ, Ruscin JM. A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. J Clin Epidemiol. 2004 ; 57 (4). 422-428
36. Sheen E, Triadafilopoulos G. Adverse effects of long-term proton pump inhibitor therapy. Dig Dis Sci. 201 ; 56 (4). 931-950
37. Hirschowitz BI, Worthington J, Mohnen J. Vitamin B12 deficiency in hypersecretors during long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther. 2008 ; 27 (11). 1110-1121
38. El-Hajj Fuleihan G, Dib L, Yamout B, Sawaya R, Mikati MA. Predictors of bone density in ambulatory patients on antiepileptic drugs. Bone. 2008 ; 43 (1). 149-155
39. Menon B, Harinarayan CV. The effect of anti epileptic drug therapy on serum 25-hydroxyvitamin D and parameters of calcium and bone metabolism - a longitudinal study. Seizure. 2010 ; 19 (3). 153-158
40. Moro-Alvarez MJ, Díaz Curiel M, de la Piedra C, Mariñoso ML, Carrascal MT. Bone disease induced by phenytoin therapy: clinical and experimental study. Eur Neurol. 2009 ; 62 (4). 219-230
41. Mueller BA, Brierton DG, Abel SR, et al. Effect of enteral feeding with ensure on oral bioavailabilities of ofloxacin and ciprofloxacin. Antimicrob Agents Chemother. 1994 ; 38 (9). 2101-2105
42. Cohn SM, Sawyer MD, Burns GA, et al. Enteric absorption of ciprofloxacin during tube feeding in the critically ill. J Antimicrob Chemother. 1996 ; 38 (5). 871-876
43. Mimoz O, Binter V, Jacolot A, et al. Pharmacokinetics and absolute bioavailability of ciprofloxacin administered through a nasogastric tube with continuous enteral feeding to critically ill patients. Intensive Care Med. 1998 ; 24 (10). 1047-1051
44. Wright DH, Pietz SL, Konstantinides FN, et al. Decreased in vitro fluoroquinolone concentrations after admixture with an enteral feeding formulation. JPEN J Parenter Enteral Nutr. 2000 ; 24 (1). 42-48
45. Bauer LA. Interference of oral phenytoin absorption by continuous nasogastric feedings. Neurology. 1982 ; 32: 570-572
46. Dickerson RN, Garmon WM, Kuhl DA, et al. Vitamin K-independent warfarin resistance after concurrent administration of warfarin and continuous enteral nutrition. Pharmacotherapy. 2008 ; 28 (3). 308-313
47. Dickerson RN. Warfarin resistance and enteral tube feeding: a vitamin K-independent interaction. Nutrition. 2008 ; 24 (10). 1048-1052
48. Dickerson RN, Maish GO, Minard G, et al. Clinical relevancy of the levothyroxine-continuous enteral nutrition interaction. Nutr Clin Pract. 2010 ; 25 (6). 646-652
49. Au Yeung SC, Ensom MH. Phenytoin and enteral feedings: does evidence support an interaction?. Ann Pharmacother. 2000 ; 34 (7-8). 896-905
50. Chan L-N. To hold (enteral feeding) or not to hold: that is the question; a commentary and tutorial. Pract Gastroenterol. 2012 ; (101). 13 19-16 21